Cepheid (CPHD) PT Raised to $72 at MKM Partners
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Wedbush Cuts Price Target to $66 on Cepheid (CPHD) Following 2Q15
July 24, 2015 10:13 AM EDTWedbush reiterated an Outperform rating on Cepheid (NASDAQ: CPHD), and cut the price target to $66.00 (from $67.00), following 2Q15 results. CPHD reported 2Q15 sales of $133 MM compared to $131 MM estimates. Reported GAAP EPS was ($0.23), compared with consensus EPS loss of ($0.21).
Analyst Zarak Khurshid commented,... More
Needham & Company Raises Price Target to $70 on Cepheid (CPHD) Following 2Q15
July 24, 2015 7:34 AM EDTNeedham & Company reiterated a Buy rating on Cepheid (NASDAQ: CPHD), and raised the price target to $70.00 (from $66.00), following 2Q15 results. Revenue was $132.5M vs. consensus of $130.5M. Non-GAAP EPS was reported at ($0.23) vs. consensus of ($0.21).
Analyst Mike Matson commented, "CPHD's 2Q15 revenue beat... More
UPDATE: Evercore ISI Downgrades Cepheid (CPHD) to Sell; Analyst Sees Risk of Multiple Compression
July 24, 2015 6:46 AM EDT(Updated - July 24, 2015 8:28 AM EDT)
Evercore ISI downgraded Cepheid (NASDAQ: CPHD) from Hold to Sell with a price target of $53.50. Analyst Vijay Kumar noted a 42% rally since April and warned slowing growth and Q4 risk could lead to multiple compression.
"Shares of CPHD have rallied ~42% since reporting earnings on 4/23 vs. the S&P 500 at ~12%, largely due to strength in 1Q commercial clinical revenues, optimism around new product pipeline... More
Cepheid (CPHD) Tops Q2 EPS by 15c
July 23, 2015 4:41 PM EDTCepheid (NASDAQ: CPHD) reported Q2 EPS of ($0.06), $0.15 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $132.5 million versus the consensus estimate of $130.7 million.
For earnings history and earnings-related data on Cepheid (CPHD) click here.
... More